MAIA Biotechnology Raises $30 Million Through 20M-Share Public Offering
MAIA Biotechnology closed a public offering of 20 million common shares at $1.50 per share, raising $30 million in gross proceeds and granting underwriters a 30-day option for an additional 3 million shares. Net proceeds will fund clinical trials, working capital, and general corporate purposes.
1. Offering Details
MAIA Biotechnology completed an underwritten public offering of 20 million common shares priced at $1.50 each, generating $30 million in gross proceeds. The company granted underwriters a 30-day option to purchase up to 3 million additional shares at the same price to cover over-allotments.
2. Use of Proceeds
The company intends to use net proceeds from the offering to advance clinical trials for its lead candidate ateganosine, as well as for working capital and general corporate purposes.
3. Underwriting and Investors
Healthcare-dedicated investors participated alongside existing shareholders in the offering, with Konik Capital Partners acting as sole book-running manager.